bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table and Figure Legends from The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis
Authors: Deel Michael D. , Slemmons Katherine K. , Hinson Ashley R. , Genadry Katia C. , Burgess Breanne A. , Crose Lisa E.S. , Kuprasertkul Nina , Oristian Kristianne M. , Bentley Rex C. , Linardic Corinne M.
Published: April 2023

Supplementary Table and Figure Legends
Figure S4 from The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis
Authors: Deel Michael D. , Slemmons Katherine K. , Hinson Ashley R. , Genadry Katia C. , Burgess Breanne A. , Crose Lisa E.S. , Kuprasertkul Nina , Oristian Kristianne M. , Bentley Rex C. , Linardic Corinne M.
Published: April 2023

Supporting data examining the effect of TAZ loss or gain of function on aRMS and C2C12 cellular phenotypes.
Supplementary Figure 4 from Vitamin D–Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription
Authors: Huang Yu-Fang , Wu Yi-Hui , Cheng Wen-Fang , Peng Shu-Ling , Shen Wan-Lin , Chou Cheng-Yang
Published: April 2023

DBP expression in cancer cells and culture media from different ovarian cancer cell lines
Supplementary Figures from Epigenome-wide SRC-1–Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer
Authors: Ward Elspeth , Varešlija Damir , Charmsaz Sara , Fagan Ailis , Browne Alacoque L. , Cosgrove Nicola , Cocchiglia Sinéad , Purcell Siobhan P. , Hudson Lance , Das Sudipto , O'Connor Darran , O'Halloran Philip J. , Sims Andrew H. , Hill Arnold D. , Young Leonie S.
Published: April 2023

Figure S1. SRC-1 dependent transcriptome in endocrine resistant LY2 cells. Figure S2. Pathways enriched in SRC-1 repressed gene set. Figure S3. Repression gene set is directly regulated and suppressed by SRC-1. Figure S4. SRC-1 mediates endocrine treatment resistant phenotype Figure S5. Expression validation for functional experiments. Figure S6. Target gene set expression in untreated ER positive population Figure S7. RG-108 treatment can drive re-expression of suppressed target gene set. Figure S8: Nuclear receptor binding activity to the SRC-1 target genes.
Figure S3 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
Authors: Ribba Benjamin , Boetsch Christophe , Nayak Tapan , Grimm Hans Peter , Charo Jehad , Evers Stefan , Klein Christian , Tessier Jean , Charoin Jean Eric , Phipps Alex , Pisa Pavel , Teichgräber Volker
Published: April 2023

Supplementary Figure S3: Comparison of QW versus Q2W CEA-IL2v dosing schedule. Top panel: Predicted pharmacokinetic population profile from cycle 1 to 4 at 20 mg QW (left); Predicted corresponding tumor uptake (right). Bottom panel: same two graphics for Q2W schedule (pharmacokinetic - left, and tumor uptake - right).
Supplementary Figure S1 from Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the IDH1 Mutation Status
Authors: Uckermann Ortrud , Juratli Tareq A. , Galli Roberta , Conde Marina , Wiedemuth Ralf , Krex Dietmar , Geiger Kathrin , Temme Achim , Schackert Gabriele , Koch Edmund , Steiner Gerald , Kirsch Matthias
Published: April 2023

Western Blot analysis of genetically engineered IDH1-wt and IDH1-mut cell lines.
Supp Table 1 from A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers
Authors: Zhu Shoumin , Chen Zheng , Wang Lihong , Peng Dunfa , Belkhiri Abbes , Lockhart A. Craig , El-Rifai Wael
Published: April 2023

Supp Table 1
Supplementary Figure S2 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
Authors: Mason Nicola J. , Gnanandarajah Josephine S. , Engiles Julie B. , Gray Falon , Laughlin Danielle , Gaurnier-Hausser Anita , Wallecha Anu , Huebner Margie , Paterson Yvonne
Published: April 2023

ADXS31-164 does not adversely affect cardiac function.
Supplemental legend from Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors
Authors: Asiedu Michael K. , Thomas Charles F. , Dong Jie , Schulte Sandra C. , Khadka Prasidda , Sun Zhifu , Kosari Farhad , Jen Jin , Molina Julian , Vasmatzis George , Kuang Ray , Aubry Marie Christine , Yang Ping , Wigle Dennis A.
Published: April 2023

Supplemental legend
Figure S1 from Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors
Authors: Asiedu Michael K. , Thomas Charles F. , Dong Jie , Schulte Sandra C. , Khadka Prasidda , Sun Zhifu , Kosari Farhad , Jen Jin , Molina Julian , Vasmatzis George , Kuang Ray , Aubry Marie Christine , Yang Ping , Wigle Dennis A.
Published: April 2023

Pathway analysis of significantly mutated genes
Supplemental Figures from Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function
Authors: Stiff Andrew , Trikha Prashant , Mundy-Bosse Bethany , McMichael Elizabeth , Mace Thomas A. , Benner Brooke , Kendra Kari , Campbell Amanda , Gautam Shalini , Abood David , Landi Ian , Hsu Vincent , Duggan Megan , Wesolowski Robert , Old Matthew , Howard John Harrison , Yu Lianbo , Stasik Nancy , Olencki Thomas , Muthusamy Natarajan , Tridandapani Susheela , Byrd John C. , Caligiuri Michael , Carson William E.
Published: April 2023

Supplemental Figures
Supplementary Data from FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma
Authors: Erbe Amy K. , Wang Wei , Goldberg Jacob , Gallenberger Mikayla , Kim KyungMann , Carmichael Lakeesha , Hess Dustin , Mendonca Eneida A. , Song Yiqiang , Hank Jacquelyn A. , Cheng Su-Chun , Signoretti Sabina , Atkins Michael , Carlson Alexander , Mier James W. , Panka David J. , McDermott David F. , Sondel Paul M.
Published: April 2023

Supplementary Table 1. Frequency of FCGR genotypes and HWE test. Supplementary Table 2. PFS Clinical Outcome Assessment of FCGR2A, FCGR3A and FCGR2C SNPs. Supplementary Table 3. Clinical Outcome Parameters were Assessed for FCGR3A, FCGR2A and FCGR2C SNPs within the Group of 100 Patients with Clear Cell Histology that were Genotyped.
Table s1 from Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance
Authors: Suenaga Masaya , Yu Jun , Shindo Koji , Tamura Koji , Almario Jose Alejandro , Zaykoski Christopher , Witmer P. Dane , Fesharakizadeh Shahriar , Borges Michael , Lennon Anne-Marie , Shin Eun-Ji , Canto Marcia Irene , Goggins Michael
Published: April 2023

Primer information
Supplementary Data (11 Supplementary Figures and 5 Supplementary Tables) from Sustained Mutant KIT Activation in the Golgi Complex Is Mediated by PKC-θ in Gastrointestinal Stromal Tumors
Authors: Kim Won Kyu , Yun SeongJu , Park Cheol Keun , Bauer Sebastian , Kim Jiyoon , Lee Min Goo , Kim Hoguen
Published: April 2023

Supplementary Figure S1. Mutant KITs show characteristic intracellular localization in GISTs. Supplementary Figure S2. Mutant KITs are expressed as the core-glycosylated immature form. Supplementary Figure S3. WT-KIT expression in small cell lung cancer (SCLC) cell lines Supplementary Figure S4. PKC-Î¸ is autophosphorylated in various cell lines transfected with the PKC-Î¸ expression vector. Supplementary Figure S5. Mutant KITs colocalize with PKC-Î¸ in GIST cell lines. Supplementary Figure S6. Down-regulation of PKC-Î¸ by siRNA induces dramatic decrease of endogenous MT-KIT expression and perturbs colocalization of endogenous MT-KITs with the Golgi in GIST cell lines. Supplementary Figure S7. Kinase activity of PKC-Î¸ is crucial for protein stability and cellular localization of MT-KITs. Supplementary Figure S8. PKC-Î¸ significantly induces an increase in activated KITs. Supplementary Figure S9. Kaplan-Meier analysis of 50 GIST patients according to PKC-Î¸ expression Supplementary Figure S10. Kaplan-Meier analysis of 154 GIST patients according to KIT mutation status Supplementary Figure S11. A schematic model of the roles of PKC-Î¸ as the MT-KIT regulating factor in GISTs Supplementary Table S1. Primers used for qRT-PCR and construction of expression vectors Supplementary Table S2. Clinicopathologic and genetic status of 154* GIST tissues Supplementary Table S3. Clinicopathological characteristics of 50 GISTs according to PKC-Î¸ and PKC-Î' expression Supplementary Table S4. Clinicopathological characteristics of 154 GISTs according to the PKC-Î¸ overexpression Supplementary Table S5. Multivariate analysis of 154 GISTs for the impact of variable clinicopathologic factors on recurrence/metastasis and survival
supplemental figures from The RARS–MAD1L1 Fusion Gene Induces Cancer Stem Cell–like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma
Authors: Zhong Qian , Liu Zhi-Hua , Lin Zhi-Rui , Hu Ze-Dong , Yuan Li , Liu Yan-min , Zhou Ai-Jun , Xu Li-Hua , Hu Li-Juan , Wang Zi-Feng , Guan Xin-Yuan , Hao Jia-Jie , Lui Vivian W.Y. , Guo Ling , Mai Hai-Qiang , Chen Ming-Yuan , Han Fei , Xia Yun-Fei , Grandis Jennifer R. , Zhang Xing , Zeng Mu-Sheng
Published: April 2023

S1. Identification of RARS-MAD1L1 by RNA-Seq. S2. RARS-MAD1L1 promotes the proliferation and colony-formation ability of p53-/- MEFs and S26 cells. S3. RARS-MAD1L1 enhances CSC properties in NPC cells. S4. Knockdown of endogenous RARS-MAD1L1 reduces the CSC characteristics of C666-1 cells. S5. Knockdown of RARS-MAD1L1 reduces the oncogenic function of S26 cells induced by RARS-MAD1L1. S6. RARS-MAD1L1 overexpression presents a stronger oncogenic function than wild-type RARS in NPC cells. S7. Knockdown of c-Myc reduces the expression of ABCG2 S8. Schematic illustration of the mechanism through which RARS-MAD1L1 induces cancer stem cell properties and therapeutic resistance through the FBP1/c-Myc axis.
Supplementary Figures from Intratumoral HPV16-Specific T Cells Constitute a Type I–Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer
Authors: Welters Marij J.P. , Ma Wenbo , Santegoets Saskia J.A.M. , Goedemans Renske , Ehsan Ilina , Jordanova Ekaterina S. , van Ham Vanessa J. , van Unen Vincent , Koning Frits , van Egmond Sylvia I. , Charoentong Pornpimol , Trajanoski Zlatko , van der Velden Lilly-Ann , van der Burg Sjoerd H.
Published: April 2023

Supplementary Figure S1. Handling of oropharyngeal squamous cell carcinoma (OPSCC) material. Supplementary Figure S2. HPV16-positive OPSCC harbor T-cells that specifically recognize the HPV16 oncoproteins E6 and E7. Supplementary Figure S3. High expression of HPV16 antigens by HPV16-positive OPSCC results in induction of HPV16-specific T-cells. Supplementary Figure S4. PHA stimulation of TILs results in differential cytokine production in the various groups of OPSCC patients. Supplementary Figure S5. Mass cytometry analysis reveals importance of CD161 and CD103 expressing intratumoral T-cells in HPV16-positive OPSCC. Supplementary Figure S6. T-helper supernatant neutralizes the type 2 macrophage-like skewing effect of OPSCC tumors. Supplementary Figure S7. Sensitivity and resistance of OPSCC tumor cell lines. Supplementary Figure S8. HPV16-specific CD161+ T-cells are important for controlling the disease.
Supplementary Data from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo
Authors: Laszlo Viktoria , Valko Zsuzsanna , Kovacs Ildiko , Ozsvar Judit , Hoda Mir Alireza , Klikovits Thomas , Lakatos Dora , Czirok Andras , Garay Tamas , Stiglbauer Alexander , Helbich Thomas H. , Gröger Marion , Tovari Jozsef , Klepetko Walter , Pirker Christine , Grusch Michael , Berger Walter , Hilberg Frank , Hegedus Balazs , Dome Balazs
Published: April 2023

Supplementary Data
Figure S8 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Authors: Puhr Martin , Hoefer Julia , Eigentler Andrea , Ploner Christian , Handle Florian , Schaefer Georg , Kroon Jan , Leo Angela , Heidegger Isabel , Eder Iris , Culig Zoran , Van der Pluijm Gabri , Klocker Helmut
Published: April 2023

Analysis of GR/AR mRNA and protein expression in long-term abiraterone treated LNCaPabl, DUCaP, and LAPC4 after (>10 mo) of cultivation in the presence of abiraterone or vehicle-ctrl (EtOH) was performed by qRT-PCR and Western blot, respectively.
Figure S7 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Authors: Puhr Martin , Hoefer Julia , Eigentler Andrea , Ploner Christian , Handle Florian , Schaefer Georg , Kroon Jan , Leo Angela , Heidegger Isabel , Eder Iris , Culig Zoran , Van der Pluijm Gabri , Klocker Helmut
Published: April 2023

(A) Representative pictures of parental and long-term abiraterone treated LNCaPabl, DUCaP, and LAPC4 cells.
Figure S11 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Authors: Puhr Martin , Hoefer Julia , Eigentler Andrea , Ploner Christian , Handle Florian , Schaefer Georg , Kroon Jan , Leo Angela , Heidegger Isabel , Eder Iris , Culig Zoran , Van der Pluijm Gabri , Klocker Helmut
Published: April 2023

(A) GR and AR protein expression in abl sub-lines after inhibition of GR or AR expression and activity using 40 nM siGR/AR for 2 d and 12 µM RU-486/4 µM enzalutamide for 1 d prior to 8 h dexamethasone (1 µM) treatment.
Figure S1 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Authors: Puhr Martin , Hoefer Julia , Eigentler Andrea , Ploner Christian , Handle Florian , Schaefer Georg , Kroon Jan , Leo Angela , Heidegger Isabel , Eder Iris , Culig Zoran , Van der Pluijm Gabri , Klocker Helmut
Published: April 2023

(A, B) GR antibody specificity test in DU145 cells using 40 nM scrambled siRNA (siCtrl), 40 nM ON-TARGETplus GR siRNA (siGR), and 1 µg pCMV6-XL5 GR overexpression plasmid for 72 h by (A) Western blot and (B) IHC.
Supplementary Figure S5 from Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats
Authors: Zhang Xiyuan , Cook Katherine L. , Warri Anni , Cruz Idalia M. , Rosim Mariana , Riskin Jeffrey , Helferich William , Doerge Daniel , Clarke Robert , Hilakivi-Clarke Leena
Published: April 2023

Proliferation and apoptosis indexes in the mammary glands and tumors of genistein (GEN) fed and tamoxifen (TAM) treated rats.
Supplementary Figure S2 from Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats
Authors: Zhang Xiyuan , Cook Katherine L. , Warri Anni , Cruz Idalia M. , Rosim Mariana , Riskin Jeffrey , Helferich William , Doerge Daniel , Clarke Robert , Hilakivi-Clarke Leena
Published: April 2023

Histopathology of mammary tumors before and during TAM treatment in GEN fed rats.
Supplementary Tables (S1-S8) from Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer
Authors: Wang Chao , Peng Guang , Huang Hai , Liu Fei , Kong De-Pei , Dong Ke-Qin , Dai Li-He , Zhou Zhe , Wang Kai-Jian , Yang Jun , Cheng Yan-Qiong , Gao Xu , Qu Min , Wang Hong-Ru , Zhu Feng , Tian Qin-Qin , Liu Dan , Cao Li , Cui Xin-Gang , Xu Chuan-Liang , Xu Dan-Feng , Sun Ying-Hao
Published: April 2023

Supplementary Tables (S1-S8)
Tables S1-S4 from The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Authors: Aisner Dara L. , Sholl Lynette M. , Berry Lynne D. , Rossi Michael R. , Chen Heidi , Fujimoto Junya , Moreira Andre L. , Ramalingam Suresh S. , Villaruz Liza C. , Otterson Gregory A. , Haura Eric , Politi Katerina , Glisson Bonnie , Cetnar Jeremy , Garon Edward B. , Schiller Joan , Waqar Saiama N. , Sequist Lecia V. , Brahmer Julie , Shyr Yu , Kugler Kelly , Wistuba Ignacio I. , Johnson Bruce E. , Minna John D. , Kris Mark G. , Bunn Paul A. , Kwiatkowski David J.
Published: April 2023

Supplemental Table 1. Institutions and PIs participating in LCMC II; Supplemental Table 2. Overview of mutational profiling platforms employed across 16 LCMC2 testing sites; Supplemental Table 3. Mutations in the core genes assayed in LCMC II; Supplemental Table 4. Massively parallel sequencing (MPS) assays employed by LCMCII institutions.
Supplementary Figures and Legends (S1-S6) from Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer
Authors: Wang Chao , Peng Guang , Huang Hai , Liu Fei , Kong De-Pei , Dong Ke-Qin , Dai Li-He , Zhou Zhe , Wang Kai-Jian , Yang Jun , Cheng Yan-Qiong , Gao Xu , Qu Min , Wang Hong-Ru , Zhu Feng , Tian Qin-Qin , Liu Dan , Cao Li , Cui Xin-Gang , Xu Chuan-Liang , Xu Dan-Feng , Sun Ying-Hao
Published: April 2023

Supplementary Figures and Legends (S1-S6)
Supplementary Table 2 from A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia
Authors: Amin Nisar A. , Seymour Erlene , Saiya-Cork Kamlai , Parkin Brian , Shedden Kerby , Malek Sami N.
Published: April 2023

listing of details of all recurrently mutated genes in 61 relapsed CLL cases
Supplementary Table 1 from Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response
Authors: Muckenhuber Alexander , Berger Anne Katrin , Schlitter Anna Melissa , Steiger Katja , Konukiewitz Björn , Trumpp Andreas , Eils Roland , Werner Jens , Friess Helmut , Esposito Irene , Klöppel Günter , Ceyhan Güralp O. , Jesinghaus Moritz , Denkert Carsten , Bahra Marcus , Stenzinger Albrecht , Sprick Martin R. , Jäger Dirk , Springfeld Christoph , Weichert Wilko
Published: April 2023

Cohort characteristics
Supplementary Figure 1 from Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response
Authors: Muckenhuber Alexander , Berger Anne Katrin , Schlitter Anna Melissa , Steiger Katja , Konukiewitz Björn , Trumpp Andreas , Eils Roland , Werner Jens , Friess Helmut , Esposito Irene , Klöppel Günter , Ceyhan Güralp O. , Jesinghaus Moritz , Denkert Carsten , Bahra Marcus , Stenzinger Albrecht , Sprick Martin R. , Jäger Dirk , Springfeld Christoph , Weichert Wilko
Published: April 2023

Frequency distributions of IHC-derived subtypes of PDAC and unclassifiable cases (purple) in all cohorts investigated in this study.
Supplement CLEAN from Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer
Authors: Ratcliffe Marianne J. , Sharpe Alan , Midha Anita , Barker Craig , Scott Marietta , Scorer Paul , Al-Masri Hytham , Rebelatto Marlon C. , Walker Jill
Published: April 2023

Supplementary Table S1. Comparison of PD-L1 diagnostic assays for patients with NSCLC Supplementary Table S2. Detailed scoring criteria for each assay in the study Supplementary Table S3. Demographics of patients who provided study samples Supplementary Table S4. OPA for pairwise assay comparisons across the full assay range
Supplementary Figures S1-S4 and Table S1 from Genome-wide DNA Methylation Profiling Reveals Methylation Markers Associated with 3q Gain for Detection of Cervical Precancer and Cancer
Authors: Verlaat Wina , Snijders Peter J.F. , Novianti Putri W. , Wilting Saskia M. , De Strooper Lise M.A. , Trooskens Geert , Vandersmissen Johan , Van Criekinge Wim , Wisman G. Bea A. , Meijer Chris J.L.M. , Heideman Daniëlle A.M. , Steenbergen Renske D.M.
Published: April 2023

Figure S1: Overview of MSP results in Verification II. Figure S2: Representative MSP results in cervical tissue specimens. Figure S3: Validation of GHSR, SST and ZIC1 by qMSP in hrHPV-positive cervical scrapes. Figure S4: No association of FAM19A4, CADM1, MAL and miR124-2 methylation levels with 3q gain. Table S1: Number of samples used per study item.
Figure S2 from Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer
Authors: Bang Yung-Jue , Cho Jae Yong , Kim Yeul Hong , Kim Jin Won , Di Bartolomeo Maria , Ajani Jaffer A. , Yamaguchi Kensei , Balogh Agnes , Sanchez Teresa , Moehler Markus
Published: April 2023

Figure S2 shows Overall Survival
Figure S1 from Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer
Authors: Bang Yung-Jue , Cho Jae Yong , Kim Yeul Hong , Kim Jin Won , Di Bartolomeo Maria , Ajani Jaffer A. , Yamaguchi Kensei , Balogh Agnes , Sanchez Teresa , Moehler Markus
Published: April 2023

Figure S1 shows Progression Free Survival
Supplementary Table 1: Selected DNA repair targeted therapies from Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
Authors: Stover Elizabeth H. , Konstantinopoulos Panagiotis A. , Matulonis Ursula A. , Swisher Elizabeth M.
Published: April 2023

Supplementary Table 1: Selected DNA repair targeted therapies
Supplementary Figure 4 from Survival and Proliferation of Neural Progenitor–Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism
Authors: Calinescu Anda-Alexandra , Yadav Viveka Nand , Carballo Erica , Kadiyala Padma , Tran Dustin , Zamler Daniel B. , Doherty Robert , Srikanth Maithreyi , Lowenstein Pedro Ricardo , Castro Maria Graciela
Published: April 2023

CXCL12 has highest expression in GBM cells induced with NRAS/SV40 LgT.
Suppl Table 4 from The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA
Authors: Parpart-Li Sonya , Bartlett Bjarne , Popoli Maria , Adleff Vilmos , Tucker Laura , Steinberg Rebecca , Georgiadis Andrew , Phallen Jill , Brahmer Julie , Azad Nilo , Browner Ilene , Laheru Daniel , Velculescu Victor E. , Sausen Mark , Diaz Luis A.
Published: April 2023

Genes Included in the Plasma Panel for Detection of Somatic Alterations by Next-Generation Sequencing
Supplementary legend from Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients
Authors: Hu Yuebi , Alden Ryan S. , Odegaard Justin I. , Fairclough Stephen R. , Chen Ruthia , Heng Jennifer , Feeney Nora , Nagy Rebecca J. , Shah Jayshree , Ulrich Bryan , Gutierrez Martin , Lanman Richard B. , Garber Judy E. , Paweletz Cloud P. , Oxnard Geoffrey R.
Published: April 2023

Supplementary legend
Supplementary Materials and Methods from Phospholipase D1 Inhibition Linked to Upregulation of ICAT Blocks Colorectal Cancer Growth Hyperactivated by Wnt/β-Catenin and PI3K/Akt Signaling
Authors: Kang Dong Woo , Lee Bo Hui , Suh Young-Ah , Choi Yong-Seok , Jang Se Jin , Kim Yong Man , Choi Kang-Yell , Min Do Sik
Published: April 2023

Supplementary Materials
Supplementary Figure S2 from Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Authors: Gray Jhanelle E. , Heist Rebecca S. , Starodub Alexander N. , Camidge D. Ross , Kio Ebenezer A. , Masters Gregory A. , Purcell W. Thomas , Guarino Michael J. , Misleh Jamal , Schneider Charles J. , Schneider Bryan J. , Ocean Allyson , Johnson Tirrell , Gandhi Leena , Kalinsky Kevin , Scheff Ronald , Messersmith Wells A. , Govindan Serengulam V. , Maliakal Pius P. , Mudenda Boyd , Wegener William A. , Sharkey Robert M. , Goldenberg David M.
Published: April 2023

Immunohistology expression of Trop-2 vs response
Supplementary Figure S1 from Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Authors: Gray Jhanelle E. , Heist Rebecca S. , Starodub Alexander N. , Camidge D. Ross , Kio Ebenezer A. , Masters Gregory A. , Purcell W. Thomas , Guarino Michael J. , Misleh Jamal , Schneider Charles J. , Schneider Bryan J. , Ocean Allyson , Johnson Tirrell , Gandhi Leena , Kalinsky Kevin , Scheff Ronald , Messersmith Wells A. , Govindan Serengulam V. , Maliakal Pius P. , Mudenda Boyd , Wegener William A. , Sharkey Robert M. , Goldenberg David M.
Published: April 2023

Case Study 2: Response assessment by CT with Trop-2 expresssion by immunohistology
Supplemental Dataset 3 from Detecting the Presence and Progression of Premalignant Lung Lesions via Airway Gene Expression
Authors: Beane Jennifer , Mazzilli Sarah A. , Tassinari Anna M. , Liu Gang , Zhang Xiaohui , Liu Hanqiao , Buncio Anne Dy , Dhillon Samjot S. , Platero Suso J. , Lenburg Marc E. , Reid Mary E. , Lam Stephen , Spira Avrum E.
Published: April 2023

GSEA results detailing lung cancer associated dataset enrichment among genes differentially expressed in the airway field associated with PMLs
Supplemental Dataset 2 from Detecting the Presence and Progression of Premalignant Lung Lesions via Airway Gene Expression
Authors: Beane Jennifer , Mazzilli Sarah A. , Tassinari Anna M. , Liu Gang , Zhang Xiaohui , Liu Hanqiao , Buncio Anne Dy , Dhillon Samjot S. , Platero Suso J. , Lenburg Marc E. , Reid Mary E. , Lam Stephen , Spira Avrum E.
Published: April 2023

Results of pathway enrichment using ROAST (FDR<0.05). The column "Direction" refers to pathway enrichment among genes up-regulated (Up) or down-regulated (Down) in the presence of PMLs.
Supplementary Figure 1C from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Authors: Kwak Jae-Yong , Kim Sung-Hyun , Oh Suk Joong , Zang Dae Young , Kim Hawk , Kim Jeong-A , Do Young Rok , Kim Hyeoung Joon , Park Joon Seong , Choi Chul Won , Lee Won Sik , Mun Yeung-Chul , Kong Jee Hyun , Chung Joo Seop , Shin Ho-Jin , Kim Dae-Young , Park Jinny , Jung Chul Won , Bunworasate Udomsak , Comia Narcisa Sonia , Jootar Saengsuree , Reksodiputro Arry Harryanto , Caguioa Priscilla B. , Lee Sung-Eun , Kim Dong-Wook
Published: April 2023

Achievement of MMR by 12 months according to 3-month EMR (< 10% of BCR-ABL1IS). (c) Radotinib 300 mg bid (n = 79 patients with evaluable molecular data at 3 months).
Supplementary Figure S5 from Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells
Authors: Katsha Ahmed , Wang Lihong , Arras Janet , Omar Omar M. , Ecsedy Jeffrey , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

Supp Fig 5
Supplementary Figure S2 from Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells
Authors: Katsha Ahmed , Wang Lihong , Arras Janet , Omar Omar M. , Ecsedy Jeffrey , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

Supp Fig 2
Supplementary figure legend from Antibody Targeting GRP78 Enhances the Efficacy of Radiation Therapy in Human Glioblastoma and Non–Small Cell Lung Cancer Cell Lines and Tumor Models
Authors: Dadey David Y.A. , Kapoor Vaishali , Hoye Kelly , Khudanyan Arpine , Collins Andrea , Thotala Dinesh , Hallahan Dennis E.
Published: April 2023

Supplementary figure legend
Supplementary Tables from The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB
Authors: Garcia-Heredia Jose Manuel , Lucena-Cacace Antonio , Verdugo-Sivianes Eva M. , Pérez Marco , Carnero Amancio
Published: April 2023

Supplementary tables 1 and 2
Supplementary Methods from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
Authors: Soler Adriana , Figueiredo Ana M. , Castel Pau , Martin Laura , Monelli Erika , Angulo-Urarte Ana , Milà-Guasch Maria , Viñals Francesc , Baselga Jose , Casanovas Oriol , Graupera Mariona
Published: April 2023

This file contains information about protein immunoblotting, histopathological analysis, and cell biological assays in cultured cells.
Supplementary Figure 5 from The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB
Authors: Garcia-Heredia Jose Manuel , Lucena-Cacace Antonio , Verdugo-Sivianes Eva M. , Pérez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure 5. Notch pathway related genes correlated with MAP17. Red color indicated positive correlations; blue color, negative correlations. Lung: P: Peitsch; Bi: Bild; E: EXPO; M: Muley; Ta: TCGA515; Tb: TCGA81; Cervix: Tc: TCGA305; A: Ahlquist; Breast: Bo: Bos; Eb: EXPO; I: Iglehart; Mi: Miller; S: Servant; So: Sotiriou; W: Wang; Td: TCGA1097; Te: TCGA528; H: Halfwerk; Colon: Ec: EXPO; O: Olschwang; Si: Sieber; Sm: Smith; D: Domany; C: Clary; Tf: TCGA286; Bu: Budinska; J: Jorissen; Ma: Marissa.
Supplementary Table 4 from Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
Authors: Chudasama Priya , Renner Marcus , Straub Melanie , Mughal Sadaf S. , Hutter Barbara , Kosaloglu Zeynep , Schweßinger Ron , Scheffler Matthias , Alldinger Ingo , Schimmack Simon , Persigehl Thorsten , Kobe Carsten , Jäger Dirk , von Kalle Christof , Schirmacher Peter , Beckhaus Marie-Kristin , Wolf Stephan , Heining Christoph , Gröschel Stefan , Wolf Jürgen , Brors Benedikt , Weichert Wilko , Glimm Hanno , Scholl Claudia , Mechtersheimer Gunhild , Specht Katja , Fröhling Stefan
Published: April 2023

Radiographic assessment of target lesions following BGJ398 treatment.
Supplementary Figure S3 from Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
Authors: Chudasama Priya , Renner Marcus , Straub Melanie , Mughal Sadaf S. , Hutter Barbara , Kosaloglu Zeynep , Schweßinger Ron , Scheffler Matthias , Alldinger Ingo , Schimmack Simon , Persigehl Thorsten , Kobe Carsten , Jäger Dirk , von Kalle Christof , Schirmacher Peter , Beckhaus Marie-Kristin , Wolf Stephan , Heining Christoph , Gröschel Stefan , Wolf Jürgen , Brors Benedikt , Weichert Wilko , Glimm Hanno , Scholl Claudia , Mechtersheimer Gunhild , Specht Katja , Fröhling Stefan
Published: April 2023

Recurrent amplification and overexpression of FRS2 in STS.
Supplementary figure 5 from Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Authors: Wang Chun-Meng , Wu Zhi-Qiang , Wang Yao , Guo Ye-Lei , Dai Han-Ren , Wang Xiao-Hui , Li Xiang , Zhang Ya-Jing , Zhang Wen-Ying , Chen Mei-Xia , Zhang Yan , Feng Kai-Chao , Liu Yang , Li Su-Xia , Yang Qing-Ming , Han Wei-Dong
Published: April 2023

Clinical response of primary-refractory HL in patients receiving CART-30 cell therapy.
Supplementary Appendix from Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Authors: Wang Chun-Meng , Wu Zhi-Qiang , Wang Yao , Guo Ye-Lei , Dai Han-Ren , Wang Xiao-Hui , Li Xiang , Zhang Ya-Jing , Zhang Wen-Ying , Chen Mei-Xia , Zhang Yan , Feng Kai-Chao , Liu Yang , Li Su-Xia , Yang Qing-Ming , Han Wei-Dong
Published: April 2023

Case selection criteria;Methods;Figure Legends
Figure S4 from Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
Authors: Wongchenko Matthew J. , McArthur Grant A. , Dréno Brigitte , Larkin James , Ascierto Paolo A. , Sosman Jeffrey , Andries Luc , Kockx Mark , Hurst Stephen D. , Caro Ivor , Rooney Isabelle , Hegde Priti S. , Molinero Luciana , Yue Huibin , Chang Ilsung , Amler Lukas , Yan Yibing , Ribas Antoni
Published: April 2023

Supplementary Figure S4. Relationship between the cell cycle and immune signatures and expression of genes associated with the neural crest phenotype described by Hoek et al (23)
Supplemental Figure 6 from Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma
Authors: Hansson Jennifer , Lindgren David , Nilsson Helén , Johansson Elinn , Johansson Martin , Gustavsson Lena , Axelson Håkan
Published: April 2023

Viability of ccRCC cell lines expressing very high or very low levels of SLC6A3 following treatment with SLC6A3 inhibitor GBR12909 with or without supplemental dopamine.
Supplemental Figure 3 from Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma
Authors: Hansson Jennifer , Lindgren David , Nilsson Helén , Johansson Elinn , Johansson Martin , Gustavsson Lena , Axelson Håkan
Published: April 2023

SLC6A3 expression and genomic copy number profiles of cell lines in the CCLE repository.
Supplemental Figure 1 from Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma
Authors: Hansson Jennifer , Lindgren David , Nilsson Helén , Johansson Elinn , Johansson Martin , Gustavsson Lena , Axelson Håkan
Published: April 2023

Heat-map visualizing transporter mRNA expression in normal and tumor tissues, with transporter gene names included.
S2: Methods for SOD2 Genotyping and Validation from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
Authors: Paller Channing J. , Zhou Xian C. , Heath Elisabeth I. , Taplin Mary-Ellen , Mayer Tina , Stein Mark N. , Bubley Glenn J. , Pili Roberto , Hudson Tamaro , Kakarla Radhika , Abbas Muneer M. , Anders Nicole M. , Dowling Donna , King Serina , Bruns Ashley B. , Wagner William D. , Drake Charles G. , Antonarakis Emmanuel S. , Eisenberger Mario A. , Denmeade Samuel R. , Rudek Michelle A. , Rosner Gary L. , Carducci Michael A.
Published: April 2023

S2 provides details on the methods used to determine and validate SOD2 germline genotypes.
Supplementary figure 2 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative
Authors: Cuppens Tine , Annibali Daniela , Coosemans An , Trovik Jone , ter Haar Natalja , Colas Eva , Garcia-Jimenez Angel , Van de Vijver Koen , Kruitwagen Roy P.M. , Brinkhuis Mariël , Zikan Michal , Dundr Pavel , Huvila Jutta , Carpén Olli , Haybaeck Johannes , Moinfar Farid , Salvesen Helga B. , Stukan Maciej , Mestdagh Carole , Zweemer Ronald P. , Massuger Leonardus F. , Mallmann Michael R. , Wardelmann Eva , Mints Miriam , Verbist Godelieve , Thomas Debby , Gommé Ellen , Hermans Els , Moerman Philippe , Bosse Tjalling , Amant Frédéric
Published: April 2023

Immunohistochemistry stainings of potential targets.
Fig. S2 from Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Chen Xin , Li Qiuhui , Liu Xin , Liu Can , Liu Ruifang , Rycaj Kiera , Zhang Dingxiao , Liu Bigang , Jeter Collene , Calhoun-Davis Tammy , Lin Kevin , Lu Yue , Chao Hsueh-Ping , Shen Jianjun , Tang Dean G.
Published: April 2023

Increased CSC marker expression in AI tumors
Supplementary data from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative
Authors: Cuppens Tine , Annibali Daniela , Coosemans An , Trovik Jone , ter Haar Natalja , Colas Eva , Garcia-Jimenez Angel , Van de Vijver Koen , Kruitwagen Roy P.M. , Brinkhuis Mariël , Zikan Michal , Dundr Pavel , Huvila Jutta , Carpén Olli , Haybaeck Johannes , Moinfar Farid , Salvesen Helga B. , Stukan Maciej , Mestdagh Carole , Zweemer Ronald P. , Massuger Leonardus F. , Mallmann Michael R. , Wardelmann Eva , Mints Miriam , Verbist Godelieve , Thomas Debby , Gommé Ellen , Hermans Els , Moerman Philippe , Bosse Tjalling , Amant Frédéric
Published: April 2023

Supplementary tables and figure legends
Supplementary Table 2 from Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer
Authors: De Robertis Mariangela , Loiacono Luisa , Fusilli Caterina , Poeta Maria Luana , Mazza Tommaso , Sanchez Massimo , Marchionni Luigi , Signori Emanuela , Lamorte Giuseppe , Vescovi Angelo Luigi , Garcia-Foncillas Jesus , Fazio Vito Michele
Published: April 2023

Supplementary Table 2A. KRAS mutational status vs. EphA2 expression (N = 70; P = 0.133{section sign}); 2B. Response rate vs. EphA2 expression (N = 68; P = 0.33{section sign}); 2C. Disease control rate vs. EphA2 expression (N = 68; P = 0.012{section sign}); 2D. Response rate vs. EphA2 expression (In KRAS WT patients; N = 39; P = 0.574{section sign}); 2E. Disease control rate vs. EphA2 expression (In KRAS WT patients; N = 39; P = 0.008{section sign})
Supplementary Table 1 from Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer
Authors: De Robertis Mariangela , Loiacono Luisa , Fusilli Caterina , Poeta Maria Luana , Mazza Tommaso , Sanchez Massimo , Marchionni Luigi , Signori Emanuela , Lamorte Giuseppe , Vescovi Angelo Luigi , Garcia-Foncillas Jesus , Fazio Vito Michele
Published: April 2023

Supplementary Table 1 - Univariate and multivariate analyses of factors affecting DFS of patients with EphA2high from pooled cohorts 1, 2, and 3 (N = 455).
Table S1-S9 from Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans
Authors: Mitchell Khadijah A. , Zingone Adriana , Toulabi Leila , Boeckelman Jacob , Ryan Bríd M.
Published: April 2023

Table S1 C2 pathway list. Table S2 C5 pathway list. Table S3 C6 pathway list. Table S4 cMap result list in AAs. Table S5 cMap result list in EAs. Table S6 Drug resistance and sensitivity comparison. Table S7 Population stratified genes in AAs. Table S8 Differentially expressed microRNAs in AAs and EAs. Table S9 Population stratified microRNAs in AAs.
Supplementary Figure 4 from Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer
Authors: De Robertis Mariangela , Loiacono Luisa , Fusilli Caterina , Poeta Maria Luana , Mazza Tommaso , Sanchez Massimo , Marchionni Luigi , Signori Emanuela , Lamorte Giuseppe , Vescovi Angelo Luigi , Garcia-Foncillas Jesus , Fazio Vito Michele
Published: April 2023

Kaplan-Meier survival curves of (A) Ptpn12 (high versus low for EphA2high group) (B) Atf2 (high versus low for EphA2high group) and (C) Pik3CG (high versus low for EphA2high group) for cohorts in which results were significant. P-values were calculated using log-rank tests. Expression value thresholds for determining high and low groups were determined through maxstat R package. Tick marks represent censored data.
Figure S5 from Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans
Authors: Mitchell Khadijah A. , Zingone Adriana , Toulabi Leila , Boeckelman Jacob , Ryan Bríd M.
Published: April 2023

Comparison of immune cell composition in lung tumors from AAs and EAs.
Supplemental Table 3 from Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome
Authors: Gasparotto Daniela , Rossi Sabrina , Polano Maurizio , Tamborini Elena , Lorenzetto Erica , Sbaraglia Marta , Mondello Alessia , Massani Marco , Lamon Stefano , Bracci Raffaella , Mandolesi Alessandra , Frate Elisabetta , Stanzial Franco , Agaj Jerin , Mazzoleni Guido , Pilotti Silvana , Gronchi Alessandro , Dei Tos Angelo Paolo , Maestro Roberta
Published: April 2023

Additional gene mutations detected in the GISTs series
Table S4 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Authors: Arbajian Elsa , Puls Florian , Antonescu Cristina R. , Amary Fernanda , Sciot Raf , Debiec-Rychter Maria , Sumathi Vaiyapuri P. , Järås Marcus , Magnusson Linda , Nilsson Jenny , Hofvander Jakob , Mertens Fredrik
Published: April 2023

SNP array findings in sclerosing epithelioid fibrosarcomas (SEF), hybrid low-grade fibromyxoid sarcomas (LGFMS)/SEF, and LGFMS.
Table S2 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Authors: Arbajian Elsa , Puls Florian , Antonescu Cristina R. , Amary Fernanda , Sciot Raf , Debiec-Rychter Maria , Sumathi Vaiyapuri P. , Järås Marcus , Magnusson Linda , Nilsson Jenny , Hofvander Jakob , Mertens Fredrik
Published: April 2023

Primers for RT-PCR detection of gene fusions
Table S1 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Authors: Arbajian Elsa , Puls Florian , Antonescu Cristina R. , Amary Fernanda , Sciot Raf , Debiec-Rychter Maria , Sumathi Vaiyapuri P. , Järås Marcus , Magnusson Linda , Nilsson Jenny , Hofvander Jakob , Mertens Fredrik
Published: April 2023

Clinical data
Supplement methodology from Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells
Authors: Tanaka Miyuki , Tashiro Haruko , Omer Bilal , Lapteva Natasha , Ando Jun , Ngo Minhtran , Mehta Birju , Dotti Gianpietro , Kinchington Paul R. , Leen Ann M. , Rossig Claudia , Rooney Cliona M.
Published: April 2023

Supplement methodology
Figure S2 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Authors: Arbajian Elsa , Puls Florian , Antonescu Cristina R. , Amary Fernanda , Sciot Raf , Debiec-Rychter Maria , Sumathi Vaiyapuri P. , Järås Marcus , Magnusson Linda , Nilsson Jenny , Hofvander Jakob , Mertens Fredrik
Published: April 2023

FACS analysis results for CD24 positivity
Figure S1 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Authors: Arbajian Elsa , Puls Florian , Antonescu Cristina R. , Amary Fernanda , Sciot Raf , Debiec-Rychter Maria , Sumathi Vaiyapuri P. , Järås Marcus , Magnusson Linda , Nilsson Jenny , Hofvander Jakob , Mertens Fredrik
Published: April 2023

Expression of MUC4 and 11p genes of interest
Supplementary Table S1 from Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy
Authors: Chaudary Naz , Pintilie Melania , Jelveh Salomeh , Lindsay Patricia , Hill Richard P. , Milosevic Michael
Published: April 2023

Tumor growth delay summary
Supp Figures from Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy
Authors: Morrow Matthew P. , Kraynyak Kimberly A. , Sylvester Albert J. , Dallas Michael , Knoblock Dawson , Boyer Jean D. , Yan Jian , Vang Russell , Khan Amir S. , Humeau Laurent , Sardesai Niranjan Y. , Kim J. Joseph , Plotkin Stanley , Weiner David B. , Trimble Cornelia L. , Bagarazzi Mark L.
Published: April 2023

Supplemental Figure 1 - Rates of CIN2/3 regression (primary endpoint) or CIN2/3 regression concomitant with clearance of HPV16 and/or HPV18 infection (secondary endpoint) in the Per Protocol population of the Phase IIb study of VGX-3100 for the treatment of biopsy proven CIN2/3 with documented HPV16 and/or HPV18 infection. Supplemental Figure 2 - Immunohistochemical analysis of CD8 infiltration at study start. The left panel shows the frequency of CD8 positive cells/mm2 as broken out by achievement of the primary endpoint of histopathological regression of CIN2/3 to CIN1 or WNL. The right panel shows the frequency of CD8 positive cells/mm2 as broken out by achievement of the primary endpoint of histopathological regression of CIN2/3 to CIN1 or WNL concomitant with elimination of HPV16/18 infection. Supplemental Figure 3 - CD137 is a marker for antigen specificity and activation on CD8+ T cells. A representative patient stain is shown for CD137 expression prior to (top) and following dosing (bottom) with VGX-3100. Whole unfractionated PBMCs were incubated with DMSO (vehicle control), OVA peptide (peptide control) HPV16 antigens, HPV18 antigens or Concanavalin A (positive control) for 120 hours. Supplemental Figure 4 - Breakdown of HPV16 and HPV18 positivity at enrollment of the study. Patients are represented as being HPV16 positive only (HPV16+ and HPV18-), HPV18 positive only (HPV16- and HPV18+) or positive for both viruses (HPV16+ and HPV18+). The bottom row represents the total patients in the study. Columns are broken into placebo and VGX-3100 cohorts and total patients in the study.
Supplementary Methods from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Authors: Pikman Yana , Alexe Gabriela , Roti Giovanni , Conway Amy Saur , Furman Andrew , Lee Emily S. , Place Andrew E. , Kim Sunkyu , Saran Chitra , Modiste Rebecca , Weinstock David M. , Harris Marian , Kung Andrew L. , Silverman Lewis B. , Stegmaier Kimberly
Published: April 2023

Supplementary Methods
Supplemental Figure 1 from Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
Authors: Infante Jeffrey R. , Hollebecque Antoine , Postel-Vinay Sophie , Bauer Todd M. , Blackwood Elizabeth M. , Evangelista Marie , Mahrus Sami , Peale Franklin V. , Lu Xuyang , Sahasranaman Srikumar , Zhu Rui , Chen Yuan , Ding Xiao , Murray Elaine R. , Schutzman Jennifer L. , Lauchle Jennifer O. , Soria Jean-Charles , LoRusso Patricia M.
Published: April 2023

Study design.
Supplementary Figure 6 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Authors: Pikman Yana , Alexe Gabriela , Roti Giovanni , Conway Amy Saur , Furman Andrew , Lee Emily S. , Place Andrew E. , Kim Sunkyu , Saran Chitra , Modiste Rebecca , Weinstock David M. , Harris Marian , Kung Andrew L. , Silverman Lewis B. , Stegmaier Kimberly
Published: April 2023

Serum drug levels in mice treated with LEE011 and dexamethasone.
Supplementary Figure 4 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Authors: Pikman Yana , Alexe Gabriela , Roti Giovanni , Conway Amy Saur , Furman Andrew , Lee Emily S. , Place Andrew E. , Kim Sunkyu , Saran Chitra , Modiste Rebecca , Weinstock David M. , Harris Marian , Kung Andrew L. , Silverman Lewis B. , Stegmaier Kimberly
Published: April 2023

LEE011 is additive with JQ1 and bortezomib and synergistic with Compound E.
Supplementary Figure S2 from In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis
Authors: Fornari Francesca , Pollutri Daniela , Patrizi Clarissa , La Bella Tiziana , Marinelli Sara , Casadei Gardini Andrea , Marisi Giorgia , Baron Toaldo Marco , Baglioni Michele , Salvatore Veronica , Callegari Elisa , Baldassarre Maurizio , Galassi Marzia , Giovannini Catia , Cescon Matteo , Ravaioli Matteo , Negrini Massimo , Bolondi Luigi , Gramantieri Laura
Published: April 2023

Figure S2. Histopathological images of HCC nodules arisen in DEN-treated rats following Sorafenib administration. Nodules that responded to Sorafenib displayed large necrotic areas.
Supplementary Figure Legend from Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy?
Authors: Goldstein Jennifer B. , Wu William , Borras Ester , Masand Gita , Cuddy Amanda , Mork Maureen E. , Bannon Sarah A. , Lynch Patrick M. , Rodriguez-Bigas Miguel , Taggart Melissa W. , Wu Ji , Scheet Paul , Kopetz Scott , You Y. Nancy , Vilar Eduardo
Published: April 2023

Supplementary Figure Legend
Supplementary File 1 from Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens
Authors: Andersen Courtney L. , Sikora Matthew J. , Boisen Michelle M. , Ma Tianzhou , Christie Alec , Tseng George , Park Yongseok , Luthra Soumya , Chandran Uma , Haluska Paul , Mantia-Smaldone Gina M. , Odunsi Kunle , McLean Karen , Lee Adrian V. , Elishaev Esther , Edwards Robert P. , Oesterreich Steffi
Published: April 2023

Supplementary File 1 contains the genes included in the "EndoRx" NanoString code set.
Suppl Table S1 from Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies
Authors: Kelly Kevin , Mejia Alex , Suhasini Avvaru N. , Lin An-Ping , Kuhn John , Karnad Anand B. , Weitman Steven , Aguiar Ricardo C.T.
Published: April 2023

Diagnosis and previous therapies for patients in the roflumilast trial.